⌘K

Home/Filings/4/0001470831-26-000007

4//SEC Filing

Lind Kevin Robert 4

Accession 0001470831-26-000007

CIK 0001534120other

View on SEC.gov Company Profile

Filed

Jan 4, 7:00 PM ET

Accepted

Jan 5, 4:05 PM ET

Size

5.3 KB

Accession

0001470831-26-000007

Insider Transaction Report

Form 4

Period: 2025-12-31

Avalo Therapeutics, Inc.AVTX

Lind Kevin Robert

Director

Transactions

Award
Stock Option (Right to Buy)
2025-12-31$14.74/sh+848$12,500→ 848 total
Exercise: $18.16Exp: 2035-12-31→ Common Stock (848 underlying)

Footnotes (1)

[F1]The options were granted on December 31, 2025, and are 100% vested.

Documents

1 file

4
form4.xmlPrimary
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Issuer

Avalo Therapeutics, Inc.

CIK 0001534120

Entity typeother

Related Parties

1

filerCIK 0001677036

Filing Metadata

Form type: 4
Filed: Jan 4, 7:00 PM ET
Accepted: Jan 5, 4:05 PM ET
Size: 5.3 KB

View on SEC.gov